Back

Pneumonia risk factors in patients with febrile neutropenia

Abstract number: p693

Aguilar-Guisado  M., Cordero  E., Cisneros  J.M., Espigado  I., Noguer   M., Parody  R., Pachón  J.

Objectives: 

To analyse risk factors of pneumonia in patients with cancer and febrile neutropenia.

Methods: 

Prospective study of all patients with cancer and febrile neutropenia admitted in Oncology or Hematology Departments. Study period: from November 2002 to February 2005. Analysed variables: demographics, kind of cancer, stage and therapy for cancer, another inmunosuppresive factor, previous antimicrobial therapy. Univariate and multivariate analysis of risk factors for pneumonia.

Results: 

Three hundred forty seven cases of febrile neutropenia were included, of which 61 had a pneumonia. Median age was 43.2 years, and 36 (59%) were males. Fifty three (87%) were patients with haematological malignancies, and 14 (23%) were blood stem-cell transplantation recipients. Risk factors for pneumonia in multivariate analysis were: previous steroid therapy (RR 2; IC95%: 1.1–3.6) and induction/consolidation chemotherapy for cancer (RR 2.3; IC95%: 1.1–5.3). In patients with haematological malignancies risk factors in multivariate analysis were previous steroid therapy (RR 2.4; IC95%: 1.1–5.5) and induction/consolidation chemotherapy for cancer (RR 2; IC95%: 1.1–3.6); In patients with solid cancer risk factors in multivariate analysis were previous antimicrobial therapy (RR 11.5; IC95%: 2–73). In patients in induction/consolidation chemotherapy for cancer, the only risk factor selected by multivariate analysis was previous therapy with quinolones (RR 2.4; 1.1–5.6).

Conclusions: 

Independent risk factors for pneumonia in patients with febrile neutropenia and haematological malignancies are previous steroid therapy and induction/consolidation chemotherapy for cancer. In patients with solid cancer, the only independent risk factor is previous antimicrobial therapy. In patients in induction/consolidation chemotherapy for cancer, it is previous quinolones therapy.

Session Details

Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Subject:
Location: Oxford, UK
Presentation type:
Back to top